RANSMITTAL LETTER Docket No. NOV 2 8 2007 (General - Patent Pending) 17120FWCCON6(AP) In Re Application Of: Bobert M. Burk TRADEAL Customer No. Group Art Unit Confirmation No. Application No. Filing Date Examiner 10/621,195 **JULY 15, 2003 ZOHREH A. FAY** 051957 1618 2332 Title: CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS **COMMISSIONER FOR PATENTS:** Transmitted herewith is: REPLY in the above identified application. □ No additional fee is required. ☐ A check in the amount of is attached. The Director is hereby authorized to charge and credit Deposit Account No. 01-0885 as described below. Charge the amount of Credit any overpayment. Charge any additional fee required. ☐ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

ROBERT J. BARAN, ESQ.
ATTORNEY OF RECORD
2372 S.E. BRISTOL STREET, SUITE B
NEWPORT BEACH, CALIFORNIA 92660-0755

TEL: (949) 851-1105 FAX: (949) 752-1925

CC:

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

NOVEMBER 26, 2007

Dated: NOVEMBER 26, 2007

Signature of Person Mailing Correspondence

ROBERT J. BARAN

Typed or Printed Name of Person Mailing Correspondence



## DOCKET NO. 17120FWCCON6(AP) PATENT

Group Art Unit: 1618

Examiner: Zohreh A. Fay

## N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of Burk

Customer No.: 051957

Serial No: 10/621,195

Conf. No.: 2332 Filed: July 15, 2003

For: CYCLOPENTANE

HEPTAN(ENE)OIC ACID, 2-

HETEROARYLALKENYL DERIVATIVES

AS THERAPEUTIC AGENTS

REPLY

Commissioner for Patents Alexandria, VA 22313-1450

Dear Sir:

In response to an Office Action dated 28 August 2007 please review the following remarks.

The claims begin on page 2 of this reply.

The remarks begin on page 6 of this reply.